this post was submitted on 09 Jul 2025
71 points (89.9% liked)

Technology

72524 readers
3621 users here now

This is a most excellent place for technology news and articles.


Our Rules


  1. Follow the lemmy.world rules.
  2. Only tech related news or articles.
  3. Be excellent to each other!
  4. Mod approved content bots can post up to 10 articles per day.
  5. Threads asking for personal tech support may be deleted.
  6. Politics threads may be removed.
  7. No memes allowed as posts, OK to post as comments.
  8. Only approved bots from the list below, this includes using AI responses and summaries. To ask if your bot can be added please contact a mod.
  9. Check for duplicates before posting, duplicates may be removed
  10. Accounts 7 days and younger will have their posts automatically removed.

Approved Bots


founded 2 years ago
MODERATORS
you are viewing a single comment's thread
view the rest of the comments
[–] MajinBlayze@lemmy.world 14 points 8 hours ago* (last edited 8 hours ago) (2 children)

There really needs to be a rhetorical distinction between regular machine learning and something like an llm.

I think people read this (or just the headline) and assume this is just asking grok "what interactions will my new drug flavocane have?" Where these are likely large models built on the mountains of data we have from existing drug trials

[–] shalafi@lemmy.world 2 points 47 minutes ago

Life sciences are where this sort of thing will shine.

[–] holomorphic@lemmy.world 1 points 48 minutes ago* (last edited 47 minutes ago)

Those models will almost certainly be essentially the same transformer architecture as any of the llms use; simply because they beat most other architectures in almost any field people have tried them. An llm is, after all, just classifier with an unusually large set of classes (all possible tokens) which gets applied repeatedly